Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase

Bone Marrow Transplantation

Volumn 19, Issue 12, 1997, Pages 1205-1212

  Schattenberg, A ^a,c   Preijers, F ^a   Mensink, E ^a   Bar B ^a   Schaap, N ^a   Van Geurts Kessel, A ^a   Van Der Maazen, R ^b   De Witte, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c Disision of Hematology   (Netherlands)

Author keywords

CML CP1; LFS; Survival in first or second complete remission; T cell depleted BMT

Indexed keywords

ANTHRACYCLINE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CENTRIFUGATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LEUKOCYTE TRANSFUSION; LYMPHOCYTE; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROBABILITY; RELAPSE; SIBLING; SURVIVAL; TREATMENT OUTCOME;

EID: 0030861093     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700824     Document Type: Article

References (52)

1. Thomas ED, Clift RA. Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
2. Goldman JM. Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myeloid leukemia in chronic phase: increased rate of relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
3. Devergie A, Reiffers J, Vernant JP et al. Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. Bone Marrow Transplant 1990; 5: 379-386.
4. Gratwohl A, Hermans J, Niederwieser D et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant 1993; 12: 509-516.
5. Martin PJ, Clift RA, Fisher LD et al. HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood 1988; 72: 1978-1984.
6. Mitsuyasu RT, Champlin RE, Gale RP et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. Ann Intern Med 1986; 105: 20-26.
7. Apperley JF, Jones L, Hale G et al. T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986; 1: 53-66.
8. Maraninchi D, Biaise D, Rio B et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987; 2: 175-178.
9. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
10. Schattenberg A, De Witte T, Preijers F et al. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. Blood 1990; 75: 1356-1363.
11. Horowitz MM, Gale RP. Sondel PM et al. Graft versus leukemia reaction after bone marrow transplantation. Blood 1990; 75: 555-562.
12. Hughes TP, Economou K, Mackinnon S et al. Slow evolution of chronic myeloid leukemia relapsing after BMT with T-cell depleted donor marrow. Br J Haematol 1989; 73: 462-467.
13. Cooperative Study Group on Chromosomes in Transplanted Patients. Cytogenetic follow-up of 100 patients submitted to bone marrow transplantation for Philadelphia chromosome-positive chronic myeloid leukemia. Eur J Haematol 1988; 40: 50-57.
14. Arthur CK, Apperley JF, Guo AP et al. Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. Blood 1988; 71: 1179-1186.
15. 1-positive chronic myelogenous leukemia. Bone Marrow Transplant 1990; 5: 119-127.
16. Bilhou-Nabera C, Bernard Ph, Marit G et al. Serial studies in allografted patients with chronic myeloid leukemia. Bone Marrow Transplant 1992; 9: 263-268.
17. Lange W, Snyder DS. Castro R et al. Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia. Blood 1989; 73: 1735-1741.
18. Gabert J, Lafage Mm Maraninchi D et al. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukemia patients after bone-marrow transplantation. Lancet 1989; 2: 1125-1127.
19. Bartram CR, Janssen WJG, Schmidberger M et al. Minimal residual leukaemia in chronic myeloid leukaemia patients after T-cell depleted bone-marrow transplantation. Lancet 1989; 1: 1260.
20. Martiat P, Maisin D, Philippe M et al. Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers. Br J Haematol 1990; 75: 355-358.
21. Delage R, Soiffer RJ, Dear K, Ritz J. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 1991; 78: 2759-2767.
22. Hughes TP, Morgan G, Martial P, Goldman J. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874-878.
23. Roth MS, Antin JH, Ash R et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992; 79: 276-282.
24. Cross NCP, Hughes TP, Feng L et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993; 84: 67-74.
25. Lion T, Izraeli S, Henn T et al. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992; 6: 495-499.
26. Lion T, Henn T, Gaiger A et al. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341: 275-276.
27. Thompson JD, Brodsky I, Yunis JJ. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 1992; 79: 1629-1635.
28. Cross NCP, Feng L, Chase A et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
29. Arcese W, Goldman JM, D'Arcangelo E et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 1993; 82: 3211-3219.
30. Mrsíc M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269-275.
31. Cullis JO, Schwarer P, Hughes TP et al. Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning. Br J Haematol 1992; 80: 33-39.
32. Kolb HJ, Mittermüller J, Clemm Ch et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
33. Cullis JO, Jiang YZ, Schwarer AP et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379-1381.
34. Drobyski WR, Roth MS, Thibodeau SN, Gottschall JL. Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 10: 301-304.
35. KoIb H-J, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
36. Muus P, De Witte T, Schattenberg A et al. Intensification of the conditioning regimen for allogeneic bone marrow transplantation in recipients of T-cell depleted grafts by the addition of anthracyclines. Leuk Lymphoma 1992; 7: 11-14.
37. Muus P, Donnelly P, Schattenberg A et al. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. Semin Oncol 1993; 20 (Suppl. 6): 47-53.
38. Raemaekers J, De Witte T, Schattenberg A, Van Der Lely N. Prevention of leukemic relapse after transplantation with lymphocyte depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthracyclines. Bone Marrow Transplant 1989; 4: 167-171.
39. De Witte T, Hoogenhout J, De Pauw BE et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic bone marrow transplantation. Blood 1986; 67: 1302-1308.
40. Plas A, De Witte T, Wessels J, Haanen C. A new multi-chamber counterflow centrifugation rotor with high-separation capacity and versatile potentials. Exp Hematol 1988; 16: 355-359.
41. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
42. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. Am J Med 1980; 69: 204-217.
43. Schattenberg A, Bär B, Smeets D et al. Comparison of chromosome studies on PHA-stimulated blood and unstimulated bone marrow cells in recipients of lymphocyte depleted grafts using counterflow centrifugation. Bone Marrow Transplant 1993; 11: 95-102.
44. Bär BMAM, Schattenberg A, Mensink EJBM et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 1993; 11: 513-519.
45. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chlorophorm extraction. Anal Biochem 1987; 162: 156-159.
46. Ringdén O, Hermans J, Labopin M et al for the acute and chronic leukaemia working parties of the European Group for Blood and Marrow Transplantation (EBMT). The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade 1 acute graft-versus-host disease. Leuk Lymphoma 1996; 24: 71-79.
47. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.
48. Ljungman P, Cordonnier C, de Bock R et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1995; 15: 455-460.
49. Lotzova E, Savary CA, Herberman RB. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leuk Res 1987; 11: 1059-1066.
50. Lanier LL, Kipps TJ, Phillips JH. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptor for IgG (CD16/leul 1 antigen). J Exp Med 1985; 162: 2089-2106.
51. Bär BMAM, Schattenberg A, De Man AJM et al. Influence of the conditioning regimen on erythrocyte chimerism, graft-versus-host disease and relapse after allogeneic transplantation with lymphocyte depleted marrow. Bone Marrow Transplant 1992; 10: 45-52.
52. Marks DI, Hughes TP, Szydlo R et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukemia in first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol 1992; 81: 383-390.